You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. N/A

    SBC: SRS Technologies            Topic: N/A

    N/A

    STTR Phase II 2000 Department of DefenseDefense Advanced Research Projects Agency
  2. N/A

    SBC: TIME DOMAIN CORP.            Topic: N/A

    N/A

    STTR Phase II 2000 Department of DefenseDefense Advanced Research Projects Agency
  3. Non-invasive delivery of skin-targeted tetanus vaccines

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) A major limitation with the contemporary vaccination program as a preventative measure against tetanus is the encumbrance associated with multiple needle-dependent injections. Our aim is to develop a simple method for the delivery of tetanus vaccines by topical application of an adenovirus-vectored vaccine patch. The hyp ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  4. NOVEL DOXORUBICIN ANALOGS:CARDIAC AND CYTOTOXIC EFFECTS

    SBC: GEM Pharmaceuticals            Topic: N/A

    Anthracyclines such as doxorubicin and daunorubicin are valuable anti- cancer drugs but their clinical utility is compromised by cumulative dose-dependent by a cumulative dose dependent cardiotoxicity. Anthracycline cardiotoxicity has been linked to free radical damage via mechanisms that involve disruption of iron regulation and formation of superoxide anion. Although the quinone moiety of anthra ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  5. New Broad Band Rare-Earth-Doped Glasses For Optical Fiber Communications

    SBC: KIGRE, INC.            Topic: BMDO01T001

    Kigre is developing new scalable high gain broad band rare earth doped laser oscillator/amplifier glass materials & diode pump architectures in support of high energy and high power laser applications. What's new, exciting and different about Kigre's laser glass materials and constructs is the ability to efficiently store and extract 1000-10,000x more laser power from ultra-short gain lengths and ...

    STTR Phase II 2004 Department of DefenseDefense Advanced Research Projects Agency
  6. Novel accelerated in vitro breeding for phytoremediation

    SBC: SOUTHERN SUN BIOSYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term goal of the collaboration between the USC and Southern Sun BioSystems is to create a plant breeding and remediation technology-development center which would supply hardware, protocols for breeding-selection and mass production of elite plants for nurseries and remediation businesses, with licensing and tracking mechanisms for protecting intellect ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  7. MRI Quantification of Postinfarct Myocardial Viability

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this Phase II project is to develop a novel R1-based method for MRI quantification of postinfarct myocardial viability using a commercially available contrast agent Gd(DTPA). The commercial embodiment of this method will be a software package that will convert a set of 2D cardiac MRI images to a 3D myocardial viability map, the Percent Infa ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  8. Cancer dual-targeting of an infectivity-enhance CRAd

    SBC: VECTORLOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Studies of the molecular mechanisms underlying neoplastic transformation and progression have resulted in the understanding that cancer is a genetic disease, deriving from the accumulation of a series of acquired genet ic lesions. Despite advances in chemotherapy, radiation delivery, and surgical treatment regimens, survival from many advanced cancers remains ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  9. An Integrated Optimization System for Lightening the Load of Warfighters

    SBC: CFD RESEARCH CORPORATION            Topic: N08T019

    Warfighters rely on technological equipment to ensure safety, mission effectiveness, and situational awareness. This equipment increases the capabilities of warfighters but also adds to their weight burden. This excess load could cause significant stress on the musculoskeletal system and lead to physiological deficits. The overall objective of the proposed project is to develop a system-level opti ...

    STTR Phase II 2009 Department of DefenseNavy
  10. Analysis & Adaptation of Advanced Fischer Tropsch Catalyst Structures and Resulting BOP Reductions to Fulfill Future Navy Fuel Needs

    SBC: INTRAMICRON INC            Topic: N07T027

    In the Phase I study, IntraMicron found that Microfibrous Entrapped Catalysts (MFEC) increased effective thermal conductivity by 3~12 times, improved selectivity and product yield, and significantly reduced the Balance of Plant (BOP) compared with packed beds; Ceramatec prepared novel catalysts for highly selective jet fuel production and designed a FTS modular reactor with fast external heat tran ...

    STTR Phase II 2009 Department of DefenseNavy
US Flag An Official Website of the United States Government